BioCryst Pharmaceuticals Company Insiders

BioCryst Pharmaceuticals' latest congressional trading

BioCryst Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.1031 % which means that it generated a profit of $0.1031 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2537) %, meaning that it created substantial loss on money invested by shareholders. BioCryst Pharmaceuticals' management efficiency ratios could be used to measure how well BioCryst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.18 in 2026, whereas Return On Tangible Assets are likely to drop (0.22) in 2026. At this time, BioCryst Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 82.7 M in 2026, despite the fact that Net Tangible Assets are likely to grow to (251.9 M). Common Stock Shares Outstanding is likely to rise to about 249.6 M in 2026, despite the fact that Net Loss is likely to grow to (211.3 M). BioCryst Pharmaceuticals holds a total of 248.04 Million outstanding shares. The majority of BioCryst Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BioCryst Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BioCryst Pharmaceuticals. Please pay attention to any change in the institutional holdings of BioCryst Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. On December 16, 2025, Representative Gilbert Cisneros of US Congress acquired under $15k worth of BioCryst Pharmaceuticals's common stock. Some institutional investors establish a significant position in stocks such as BioCryst Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioCryst Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BioCryst Pharmaceuticals Workforce Comparison

The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19.

BioCryst Pharmaceuticals Insider Trading History

BioCryst Pharmaceuticals Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as BioCryst Pharmaceuticals often depends on how effective the management is. BioCryst Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioCryst management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioCryst management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in BioCryst Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioCryst Pharmaceuticals. Check BioCryst Pharmaceuticals' Beneish M Score to see the likelihood of BioCryst Pharmaceuticals' management manipulating its earnings.

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.